Medpace publishes 2025 annual report on Form 10-K filing

Reuters04-02

Medpace publishes 2025 annual report on Form 10-<a href="https://laohu8.com/S/TKKD.SI">K</a> filing

Medpace filed annual report for fiscal year ended Dec. 31, 2025, outlining continued focus on full-service Phase I-IV clinical development outsourcing.
Business strategy emphasized expanding share with small and mid-sized biopharma clients, supported by therapeutic strength in areas such as oncology and CNS.
Operations highlighted proprietary ClinTrak platform as central to trial execution, real-time study metrics, and standardized processes across global programs.
Workforce scaled to about 6,200 employees across 46 countries as of Dec. 31, 2025, positioning company to support growth in global trial activity.
Competitive landscape described as fragmented, with large global CRO rivals including IQVIA, ICON, Thermo Fisher’s PPD, and Fortrea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624541858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 04:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624541858","market":"fut","top_or_hot":-1,"title":"Medpace publishes 2025 annual report on Form 10-K filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medpace publishes 2025 annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> filing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Medpace filed annual report for fiscal year ended Dec. 31, 2025, outlining continued focus on full-service Phase I-IV clinical development outsourcing.\n        </li>\n<li>\n          Business strategy emphasized expanding share with small and mid-sized biopharma clients, supported by therapeutic strength in areas such as oncology and CNS.\n        </li>\n<li>\n          Operations highlighted proprietary ClinTrak platform as central to trial execution, real-time study metrics, and standardized processes across global programs.\n        </li>\n<li>\n          Workforce scaled to about 6,200 employees across 46 countries as of Dec. 31, 2025, positioning company to support growth in global trial activity.\n        </li>\n<li>\n          Competitive landscape described as fragmented, with large global CRO rivals including IQVIA, ICON, Thermo Fisher’s PPD, and Fortrea.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MEDP\">Medpace Holdings Inc.</a> published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medpace publishes 2025 annual report on Form 10-K filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedpace publishes 2025 annual report on Form 10-K filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-02 04:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medpace publishes 2025 annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> filing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Medpace filed annual report for fiscal year ended Dec. 31, 2025, outlining continued focus on full-service Phase I-IV clinical development outsourcing.\n        </li>\n<li>\n          Business strategy emphasized expanding share with small and mid-sized biopharma clients, supported by therapeutic strength in areas such as oncology and CNS.\n        </li>\n<li>\n          Operations highlighted proprietary ClinTrak platform as central to trial execution, real-time study metrics, and standardized processes across global programs.\n        </li>\n<li>\n          Workforce scaled to about 6,200 employees across 46 countries as of Dec. 31, 2025, positioning company to support growth in global trial activity.\n        </li>\n<li>\n          Competitive landscape described as fragmented, with large global CRO rivals including IQVIA, ICON, Thermo Fisher’s PPD, and Fortrea.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MEDP\">Medpace Holdings Inc.</a> published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1791710400.SGD","symbol_name":"Fidelity Global Demographics A-ACC-SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL40DFY3:1","article_id":"2624541858","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624541858","pubTimestamp":1775075033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medpace filed annual report for fiscal year ended Dec. 31, 2025, outlining continued focus on full-service Phase I-IV clinical development outsourcing.Business strategy emphasized expanding share with small and mid-sized biopharma clients, supported by therapeutic strength in areas such as oncology and CNS.Operations highlighted proprietary ClinTrak platform as central to trial execution, real-time study metrics, and standardized processes across global programs.Workforce scaled to about 6,200 employees across 46 countries as of Dec. 31, 2025, positioning company to support growth in global trial activity.Competitive landscape described as fragmented, with large global CRO rivals including IQVIA, ICON, Thermo Fisher’s PPD, and Fortrea.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","MEDP":"Medpace Holdings Inc.","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","BK4588":"碎股","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","BK4530":"医药外包概念","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4121":"生命科学工具和服务","IQV":"艾昆纬","BK4585":"ETF&股票定投概念","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)"},"translate_title":"Medpace发布2025年10-K表格备案年度报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDP":0.9,"IQV":0.9},"content_text":"Medpace publishes 2025 annual report on Form 10-K filing\n    \n\n\n          Medpace filed annual report for fiscal year ended Dec. 31, 2025, outlining continued focus on full-service Phase I-IV clinical development outsourcing.\n        \n\n          Business strategy emphasized expanding share with small and mid-sized biopharma clients, supported by therapeutic strength in areas such as oncology and CNS.\n        \n\n          Operations highlighted proprietary ClinTrak platform as central to trial execution, real-time study metrics, and standardized processes across global programs.\n        \n\n          Workforce scaled to about 6,200 employees across 46 countries as of Dec. 31, 2025, positioning company to support growth in global trial activity.\n        \n\n          Competitive landscape described as fragmented, with large global CRO rivals including IQVIA, ICON, Thermo Fisher’s PPD, and Fortrea.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624541858","isCrawlerRequest":true}